UCI statement concerning Toon Aerts

The Union Cycliste Internationale (UCI) confirms that the Belgian cyclist Toon Aerts was notified of an Adverse Analytical Finding (AAF) for Letrozole Metabolite (Bis-4-cyano-phenyl-methanol) (1) in a sample collected during an out-of-competition control held on 19 January 2022.

The doping control was initiated and conducted by the International Testing Agency (ITA) on behalf of the UCI.

The rider has the right to request and attend the analysis of his B sample.

Letrozole and its metabolites are qualified as Specified Substances on the World Anti-Doping Agency’s Prohibited List and therefore do not require the imposition of a mandatory provisional suspension against the rider.

The UCI systematically reports potential Anti-Doping Rule Violations via its website when a mandatory provisional suspension applies. In cases where there is no mandatory provisional suspension, the UCI publicly discloses Anti-Doping Rule Violations only at the end of the proceedings, unless the existence of the AAF is made public by another party before a decision is rendered, as it is the case now.

At this stage of the procedure, the UCI will not comment any further on the matter.

(1) Letrozole and its metabolites are Prohibited Substances listed under class S4.1 (Hormone and Metabolic Modulators / Aromatase Inhibitors) of the 2022 Prohibited List which is maintained by the World Anti-Doping Agency (WADA) and adopted by the UCI.